Molecular basis for oncogenic signaling via Wnt-receptor pseudokinases
Description of the granted funding
Ovarian cancer (OC) is one of the most common gynecologic cancers that also has high mortality rate. This is due to resistant and metastatic forms of the disease that causes relapsing. Hence, there is an urgent need for new effective treatments for OC. Interestingly, it has been found that OC cells, among other types of cancer cells, have high expression of receptors that bind Wnt ligands, such as tyrosine kinase-like orphan receptor 1 and 2 (ROR1 and 2) and protein tyrosine kinase 7 (PTK7), which are not expressed at high levels in healthy adult tissues. My projects will give insight of how these Wnt-signaling receptors drive cancer progression and how by targeting their expression we could stop cancer growth. We use OC cell lines and patient-derived cells to study the oncogenic events driven by these receptors, including genes and signaling cascades they alter. In parallel, we will develop molecules that bind explicitly to these tumor-specific receptors and block their function.
Show moreStarting year
2022
End year
2026
Granted funding
Funder
Research Council of Finland
Funding instrument
Postdoctoral Researcher
Decision maker
Scientific Council for Biosciences, Health and the Environment
28.04.2022
28.04.2022
Other information
Funding decision number
349787
Fields of science
Biochemistry, cell and molecular biology
Research fields
Biokemia, biofysiikka
Identified topics
cancer